Hyporeninemic Hypoaldosteronism Questions & Answers

1. Mustaqeem R, Arif A. Renal Tubular Acidosis. StatPearls. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. J Assoc Physicians India. 2008 Sep. 56:685-93. [QxMD MEDLINE Link].

3. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol. 2009 Feb. 20(2):251-4. [QxMD MEDLINE Link].

4. Schambelan M, Sebastian A, Biglieri EG. Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int. 1980 Jan. 17(1):89-101. [QxMD MEDLINE Link].

5. Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes. 2016 Mar 10. 7 (5):101-11. [QxMD MEDLINE Link]. [Full Text].

6. Kulkarni M. Type 4 renal tubular acidosis in a kidney transplant recipient. Biomed J. 2016 Feb. 39 (1):85-6. [QxMD MEDLINE Link].

7. Lin W, Mou L, Tu H, et al. Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients. J Clin Pharm Ther. 2017 Feb. 42 (1):122-4. [QxMD MEDLINE Link].

8. Schmoyer C, Mishra S, Fulco F. Tacrolimus-Induced Type IV Renal Tubular Acidosis following Liver Transplantation. Case Reports Hepatol. 2017. 2017:9312481. [QxMD MEDLINE Link]. [Full Text].

9. Sanchez-Marcos C, Hoffman V, Prieto-Gonzalez S, Hernandez-Rodriguez J, Espinosa G. Renal tubular acidosis type IV as a complication of lupus nephritis. Lupus. 2016 Mar. 25 (3):307-9. [QxMD MEDLINE Link].

10. Porteous H, Morgan N, Lanfranco J, Garcia-Buitrago M, Young L, Lenz O. Systemic lupus erythematosus associated with type 4 renal tubular acidosis: a case report and review of the literature. J Med Case Rep. 2011 Mar 24. 5:114. [QxMD MEDLINE Link].

11. Düsing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin. 2009 Sep. 25(9):2287-301. [QxMD MEDLINE Link].

12. Estacio RO. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors. Postgrad Med. 2009 May. 121(3):33-44. [QxMD MEDLINE Link]. [Full Text].

13. Doulton TW, Macgregor GA. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. J Renin Angiotensin Aldosterone Syst. 2009 Jul 17. [QxMD MEDLINE Link].

14. Tseng MH, Huang JL, Huang SM, et al. Clinical features, genetic background, and outcome in infants with urinary tract infection and type IV renal tubular acidosis. Pediatr Res. 2020 Jun. 87 (7):1251-5. [QxMD MEDLINE Link].

15. Massolini BD, Contieri SSG, Lazarini GS, et al. Therapeutic Renin Inhibition in Diabetic Nephropathy-A Review of the Physiological Evidence. Front Physiol. 2020. 11:190. [QxMD MEDLINE Link]. [Full Text].

16. Haas CS, Pohlenz I, Lindner U, Muck PM, Arand J, Suefke S. Renal tubular acidosis type IV in hyperkalaemic patients--a fairy tale or reality?. Clin Endocrinol (Oxf). 2013 May. 78(5):706-11. [QxMD MEDLINE Link].

17. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011 Mar. 26(3):377-84. [QxMD MEDLINE Link]. [Full Text].

James H Sondheimer, MD, FACP, FASN Professor of Medicine, Nephrology and Hypertension, Department of Medicine, Wayne State University School of Medicine; Medical Director, DaVita Kresge Dialysis (Detroit)

James H Sondheimer, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology

Disclosure: Nothing to disclose.

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

The author would like to thank Dr Jaideep Hingorani for his many helpful comments and suggestions.

Additional Contributors

Donald A Feinfeld, MD, FACP, FASN Consulting Staff, Division of Nephrology & Hypertension, Beth Israel Medical Center

Donald A Feinfeld, MD, FACP, FASN is a member of the following medical societies: American Academy of Clinical Toxicology, American Society of Hypertension, American Society of Nephrology, and National Kidney Foundation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Christie P Thomas, MBBS, FRCP, FASN, FAHA Professor, Department of Internal Medicine, Division of Nephrology, Medical Director, Kidney and Kidney/Pancreas Transplant Program, University of Iowa Hospitals and Clinics

Christie P Thomas, MBBS, FRCP, FASN, FAHA is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Nephrology, and Royal College of Physicians

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article